{"id":31250,"date":"2025-08-29T18:04:06","date_gmt":"2025-08-29T18:04:06","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/31250\/"},"modified":"2025-08-29T18:04:06","modified_gmt":"2025-08-29T18:04:06","slug":"the-seven-shifts-needed-to-accelerate-longevity-science","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/31250\/","title":{"rendered":"The seven shifts needed to accelerate longevity science"},"content":{"rendered":"

McKinsey Health Institute report calls for change to facilitate the development of biomedical interventions targeting the aging process.<\/strong> <\/p>\n

A new report from the McKinsey Health Institute<\/a> (MHI) was published today, focused on how to accelerate progress in healthspan science to the benefit of society at large. Entitled,\u00a0 Healthspan science may enable healthier lives for all<\/a>, the report identifies seven key \u201cshifts\u201d that would help create the conditions to allow longevity biotech to flourish.<\/p>\n

From defining the field and improving our fundamental understanding of aging to achieving consensus on biomarkers and establishing clear regulatory pathways, the report\u2019s authors call for greater investment and leadership in longevity to enable the benefits of aging-focused interventions to be realized.<\/p>\n

Longevity.Technology: A non-profit-generating institute within consulting giant McKinsey, MHI is founded on the belief that humanity could add up to 45 billion years of higher-quality life in the next decade. The group focuses on historically under-invested areas of health to convene leaders, advance research, produce open-access data and tools, promote innovation and investment, and drive collaboration for systemic change in population health. And healthspan is squarely in its sights. To learn more, we sat down with Lars Hartenstein, director of healthy longevity at MHI, who presented the new report at the Aging Research and Drug Discovery conference<\/a> (ARDD) in Copenhagen this week.<\/strong><\/p>\n

\"\"Lars Hartenstein is director of healthy longevity at the McKinsey Health Institute. <\/p>\n

While investment in longevity biotech continues to grow, the sector still lags far behind that of other areas of health such as oncology. And this is exactly what makes it interesting to MHI, says Hartenstein.<\/p>\n

\u201cThe field is at this \u2018in-between\u2019 point \u2013 it\u2019s nascent and emerging, not yet fully investable at scale,\u201d he explains. \u201cWe\u2019ve been looking at healthy longevity from the very beginning. As the field has matured, our interest has grown but this is the first time we\u2019ve examined it through the lens of biomedical innovation.\u201d \u00a0<\/p>\n

Addressing the biology of aging has enormous theoretical potential to combat age-related diseases, which Hartenstein says account for about a third of the global disease burden.<\/p>\n

\"\"<\/a> <\/p>\n

\u201cThe economic potential is huge: using our Prioritizing Health model, we estimate that tackling just half of this burden could add about $2 trillion to global GDP,\u201d he says. \u201cSo it\u2019s an area of massive potential. The idea of the paper is to synthesize where things stand \u2013 the challenges, the opportunities for acceleration \u2013 and to argue that real progress will require broader engagement. More people need to pay attention to this field than currently are.\u201d<\/p>\n

In the report, Hartenstein and his co-authors outline seven key shifts needed to accelerate progress in healthspan science and interventions, each representing a key challenge the field currently faces:<\/p>\n